Myeloid neoplasm

Papers on myeloid neoplasm

138 papers17 new in 30 days

Wednesday, November 18

Friday, November 13

Research Square

Blood DNA screen false positives rose with age

False-positive rates rose from 0.3% below age 60 to 7.5% at 80 or older in an analysis of whole-blood samples.False-positive rates rose from 0.3% below age 60 to 7.5% at 80 or older in an analysis of whole-blood samples.

Blood cells with densely marked nuclei sit beside white-haired figures, surrounded by smaller clusters with sparse marks and dark-haired figures.
Preprint: cross-sectional studyBiomarkers

Wednesday, November 11

Saturday, November 7

Tuesday, November 3

Monday, November 2

Friday, October 30

Thursday, October 29

Tuesday, October 27

The American Journal of Clinical Nutrition

Higher ultra-processed food intake linked to some blood cancers

Higher intake was associated with more new blood cancer diagnoses among 204,494 UK Biobank participants followed for a median 10.5 years.Higher intake was associated with more new blood cancer diagnoses among 204,494 UK Biobank participants followed for a median 10.5 years.

Figure from The American Journal of Clinical Nutrition
Cohort · 204,494 peoplePopulations

Monday, October 26

Thursday, October 15

Wednesday, October 14

Nature Communications

TET2 loss alters DNA copying during drug treatment in cells

Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.

Loss of TET2, but not DNMT3A, increases fork progression and DNA damage in PARPi-treated cells.
Human cell studyTET2

Friday, October 2

Tuesday, September 29

Nature Genetics

Germline HRD limits therapy-driven clonal hematopoiesis

Serial blood samples revealed carboplatin and PARP inhibitors expand DNA damage response clones, though germline homologous recombination deficiency reduces this growth.Serial blood samples revealed carboplatin and PARP inhibitors expand DNA damage response clones, though germline homologous recombination deficiency reduces this growth.

Retrospective analysis of the MSK-IMPACT cohort shows that PARPi therapy is strongly associated with DDR CH but is confounded by exposure to prior cytotoxic therapy.
Cohort study in peopleBlood and immune system

Monday, September 21

Cancer

Vitamin C did not slow growth of mutated blood-cell groups

Median growth of mutated blood-cell groups was 0.016 per year lower with vitamin C than placebo, but the results were consistent with no difference.Median growth of mutated blood-cell groups was 0.016 per year lower with vitamin C than placebo, but the results were consistent with no difference.

EVITA trial profile. Screening, randomization, treatment, long‐term follow‐up, and analysis in the EVITA study.
Randomized trialVitamin C

Wednesday, September 16

Nature Genetics

Interferon shifted blood-cell development in cancer patients

Bone marrow samples from 10 people treated weekly for at least a year revealed parallel inflammatory and anti-inflammatory programs.Bone marrow samples from 10 people treated weekly for at least a year revealed parallel inflammatory and anti-inflammatory programs.

Figure from Nature Genetics
Cohort · 10 peopleInterventions

Sunday, September 13

Friday, September 11

Thursday, September 10

Wednesday, September 9

Friday, September 4

Saturday, August 29